Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Aldeyra Eyes NDA Resubmission for DED Treatment
Aldeyra Therapeutics announced its clinical development strategy aimed at the resubmission of a New Drug Application (NDA) for its topical ocular 0.25% reproxalap. This investigational RASP modulator is poised for the treatment of dry eye disease, pending approval from the…
Study Finds New Paths in Zika Eye Condition Treatments
Researchers at Wayne State University School of Medicine have published a study in the journal iScience, shedding light on the potential treatment targets for eye abnormalities caused by the Zika virus (ZIKV) infection during pregnancy. The Role of Cholesterol Metabolism…
Regenxbio’s Gene Therapy for Wet AMD Found Successful
Regenxbio Inc. announced the publication of their phase 1/2a study results in The Lancet, showcasing the effectiveness of ABBV-RGX-314 as a one-time gene therapy for wet age-related macular degeneration (AMD). Lancet Study Highlights Safety and Efficacy of ABBV-RGX-314 The study,…
Aurion’s First Canadian Dose in Corneal Edema Trial
Aurion Biotech has dosed the first Canadian participant in its phase 1/2 clinical trial, known as ABA-1, CLARA. The trial investigates the efficacy and safety of AURN001, a novel cell therapy aimed at treating corneal edema resulting from corneal endothelial…
Provectus & University of Miami Ink Deal on Eye Treatment
Provectus Biopharmaceuticals, Inc. has signed an exclusive global licensing agreement with the University of Miami. This partnership aims to harness the University’s pioneering photodynamic antimicrobial therapy (PDAT) for combating bacterial, fungal, and parasitic (acanthamoeba) eye infections. Launching a Start-Up for…
Opus Genetics’ LCA5 Therapy Enters Phase 1/2 Trial
Opus Genetics recently completed the first stage of its innovative clinical trial, focusing on a new treatment for patients suffering from Leber congenital amaurosis (LCA) due to biallelic mutations in the LCA5 gene. The trial, which is in the phase…
Iveric Bio Secures Key J-code for GA Therapy, Izervay
In a significant development for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), Iveric Bio, a subsidiary of Astellas Pharma, has been granted a unique, permanent J-code by the Centers for Medicare & Medicaid Services (CMS) for…
Algae-Derived Hydrogel Offers Hope for Retinal Detachment
A recent study has introduced an innovative approach to treating retinal detachment through an artificial vitreous body made from alginate, a natural carbohydrate extracted from algae. This research represents a collaboration among experts from Pohang University of Science and Technology…
BlueRock and Foundation Fighting Blindness Partner for IRD Study
BlueRock Therapeutics LP, a clinical-stage cell therapy company and a subsidiary of Bayer, in partnership with Foundation Fighting Blindness, has announced their collaboration to introduce a new cohort to the Foundation’s ‘Uni-Rare natural history study’. This initiative focuses on individuals…
Nanodropper Adaptor Proven Effective in IOP Management
In a pivotal development in the field of ophthalmology, Nanodropper Inc announced that the results from a clinical trial evaluating the Nanodropper® Adaptor have been published in the esteemed journal, Ophthalmology. The study’s findings indicate that there was no clinically…